Merck announced its Gardasil vaccine was 100% effective over the short term in preventing infection with two strains of human papillomavirus, a sexually transmitted disease that is the leading cause of cervical cancer, during a Phase III study of more than 12,000 young women in 13 countries. The company -- which said it plans to apply for FDA approval this year and perhaps bring the vaccine to market in 2006 -- said the drug was genetically engineered to block HPV types 16 and 18, which cause 70% of cervical cancers.

Related Summaries